Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Skin Neoplasms × sargramostim × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Breast Neoplasms 5 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Neuroblastoma 2 Neoplasms 2 Multiple Myeloma 2 Lung Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Adenocarcinoma 2 Wilms Tumor 1 Uterine Cervical Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rectal Neoplasms 1 Neoplasms, Plasma Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1

Interventions

fludarabine 3 Cyclophosphamide 3 pembrolizumab 2 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 sargramostim 1 reolysin 1 poly ICLC 1 peginterferon alfa-2a 1 osimertinib 1 gusacitinib 1 fludarabine phosphate 1 eprenetapopt 1 dabrafenib 1 cobimetinib 1 cemiplimab 1 Vorinostat 1 Temozolomide 1 Radiotherapy 1 Radiation 1 Poly I-C 1 Nivolumab 1 Monatide (IMS 3015) 1 Methods 1 MAPRE1 protein, human 1 Ipilimumab 1 Interleukin-15 1 Interleukin-12 1 Histone Deacetylase Inhibitors 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡